XTX Topco’s Inhibikase Therapeutics IKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$65.4K Buy
38,914
+18,616
+92% +$33.1K ﹤0.01% 3245
2025
Q4
$41.6K Buy
+20,298
New +$32.3K ﹤0.01% 2882

Other funds holding IKT

XTX Topco's IKT Position: Q1 2026 in Review

XTX Topco increased its Inhibikase Therapeutics (IKT) stake by 92% in Q1 2026, buying an estimated $33.1K and bringing the position to 38,914 shares worth $65.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3245.

XTX Topco first reported a position in IKT in Q4 2025 and has held it in 2 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • XTX Topco held 38,914 shares of Inhibikase Therapeutics worth $65.4K as of Q1 2026.
  • XTX Topco bought 18,616 Inhibikase Therapeutics shares in Q1 2026, an estimated $33.1K.
  • Inhibikase Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3245 holding.
  • XTX Topco first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.